Portal latinoamericano de toxicología
Restricted use for piroxicam, AE botulism toxin, and more
7 August, 2007
From Mariano Madurga (To e farmaco List)
- The European Medicines Agency (EMEA) has recommended restrictions on the use of piroxicam-containing medicinal products because of the risk of gastrointestinal side effects and serious skin reactions. The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that piroxicam should no longer be used for treatment of short-term painful and inflammatory [ See ]
- Note of AEMPS (only available in Spanish): RISK OF SERIOUS ADVERSE EFFECTS BY DISSEMINATION OF THE TOXIN OF BOTULISM.
- n the editorial of British Journal of Clinical Pharmacology,August 2007 Dr Aronson write: "An agenda for research on adverse drug reactions"
See also all number, including "Disease mongering – a challenge for everyone involved in healthcare" By James W. Dear & David J. Webb. Pages 122-124 - From WHO-Geneve: "Consolidated List of Products whose Consumption and/or Sale have been Banned, Withdrawn, Severely Restricted or Not Approved by Governments"
- From EMEA (European Medicines Agency) "European Risk Management Strategy: Achievements to date". See also "Public Status Report on the Implementation of the European Risk Management Strategy (Reporting Period Mid 2005 – Mid 2007)"
- MHRA published on line bulletin DRUG SAFETY UPDATE from august 2007.
(The Medicines and Healthcare products Regulatory Agency (MHRA) is the government agency which is responsible for ensuring that medicines and medical devices work, and are acceptably safe). [ See ] [ See in pdf format ]